文献速递脑血管病

轻型卒中颅内出血模式与结局:TEMPO-2试验分析

Intracranial Hemorrhage Patterns and Outcomes in Minor Stroke: Analysis of the TEMPO-2 Trial.
PubMed 文献 · Stroke · 2026-04-10

本研究为TEMPO-2随机试验的二次分析,纳入884例发病12小时内、NIHSS≤5分且伴血管闭塞或灌注 mismatch 的轻型缺血性卒中患者,比较替奈普酶与非溶栓标准治疗。结果显示任何颅内出血发生率为11.8%,与90天死亡风险升高相关(aHR 3.71),但与恢复至病前功能状态无显著关联。

要点

  • 轻型卒中后任何颅内出血与90天死亡风险增加独立相关。
  • 替奈普酶组任何颅内出血发生率高于标准治疗组,但多为点状出血转化。
  • 症状性颅内出血率两组数值上替奈普酶组更高,但差异未达统计学显著。

核心结论

  • 尽管多数出血为轻微类型,但任何颅内出血的存在与轻型缺血性卒中患者90天死亡率显著升高相关。
  • 任何颅内出血与恢复至病前功能状态无显著关联。

研究设计与样本

  • TEMPO-2多中心随机试验的二次分析,比较替奈普酶与非溶栓标准治疗。
  • 纳入发病12小时内、NIHSS≤5分且可见血管闭塞或灌注 mismatch 的轻型缺血性卒中患者。
  • 884例参与者中865例具备完整24小时影像和随访数据,用于完整病例分析。
  • 随访影像采用海德堡分类评估出血,症状性颅内出血定义为伴神经功能恶化的任何出血。
  • 主要结局为90天恢复至病前功能状态,采用改良Rankin量表测量。

主要发现

  • 任何颅内出血发生于102例参与者(11.8%)。
  • 任何颅内出血与恢复至基线神经功能无显著关联(调整OR 0.93,95%CI 0.87-1.00)。
  • 任何颅内出血与90天死亡率升高相关(9.8% vs 1.8%;调整HR 3.71,95%CI 1.54-8.95)。
  • 替奈普酶组任何颅内出血发生率高于标准治疗组(14.4% vs 9.2%;P=0.02),但多为点状出血转化。
  • 症状性颅内出血率替奈普酶组为1.9%(8例),对照组为0.5%(2例),差异无统计学意义(P=0.06)。

临床怎么用

  • 轻型缺血性卒中患者出现任何颅内出血,即使轻微,也应警惕90天死亡风险升高。
  • 替奈普酶治疗后任何颅内出血发生率较高,但多为点状出血转化,症状性出血率差异未达显著。

局限性

  • 本研究为TEMPO-2试验的二次分析,结果需在更广泛人群中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intracranial hemorrhage (ICH) negatively impacts functional outcomes after ischemic stroke, with potentially disproportionate impacts in patients with minor stroke. This study aimed to evaluate the effect of ICH on outcomes in minor ischemic stroke and to identify predictors associated with ICH. METHODS: This was a secondary analysis of the TEMPO-2 (A Randomized Controlled Trial of Tenecteplase Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion) multicenter, randomized trial, which compared tenecteplase with nonthrombolytic standard care in patients within 12 hours of symptom onset with minor stroke (National Institutes of Health Stroke Scale score ≤5) and a visible vessel occlusion or perfusion mismatch. Follow-up imaging was assessed for hemorrhage using the Heidelberg classification. Symptomatic ICH was defined as any hemorrhage associated with neurological deterioration. The primary outcome was return to premorbid functional status at 90 days, measured using the modified Rankin Scale. Mixed-effects regression was used to assess the effect of ICH status on outcomes, adjusting for treatment, age, sex, baseline stroke severity, and onset-to-randomization time, with region included as a random effect. RESULTS: Among 884 participants, 865 had complete 24-hour imaging and follow-up. Using complete case analysis (n=865), any ICH occurred in 102 participants (11.8%). Patients with any ICH (median age, 70 years; 35.3% females) more frequently had premorbid hypertension (71.6% versus 57.7%) and atrial fibrillation (28.4% versus 18.1%). Any ICH was not associated with reduced odds of returning to baseline neurological function (adjusted odds ratio, 0.93 [95% CI, 0.87-1.00]) but was associated with higher 90-day mortality (9.8% versus 1.8%; adjusted hazard ratio, 3.71 [95% CI, 1.54-8.95]). Rates of any ICH were higher in tenecteplase than standard care (14.4% versus 9.2%; P=0.02), although most were petechial hemorrhagic transformations. Symptomatic ICH rates, although numerically higher, were not significantly different between the tenecteplase versus control arms (8 [1.9%] versus 2 [0.5%]; P=0.06). CONCLUSIONS: Although most hemorrhages were minor, the presence of any ICH was strongly associated with increased mortality, highlighting that even minor hemorrhagic transformation may be prognostically significant in patients with minor ischemic stroke.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Massicotte S, Vatanpour S, Doolan C, et al. Intracranial Hemorrhage Patterns and Outcomes in Minor Stroke: Analysis of the TEMPO-2 Trial. Stroke. 2026. PMID: 41958392. doi:10.1161/STROKEAHA.125.054491

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。